(OTC BB:AMNT) , (NasdaqGS:FBTX), (OTC BB:ACTC).

RealPennies.com: Turning Pennies into dollars: (OTC BB:AMNT) , (NasdaqGS:FBTX), (OTC BB:ACTC).

Are you a public company looking for exposure?
Contact RealPennies.com - 1.800.940.6559

For more info: http://amnt.realpennies.com

Amish Naturals (OTC BB:AMNT) (February 1, 2008) announced that the company's organic pasta line will soon be available at Kings Super Markets Inc.

Customers of the upscale supermarket chain can enjoy Amish Naturals' Fettuccine, Penne and Birds Nest pastas as they begin to hit the shelves in the coming weeks at Kings' 27 retail grocery outlets located in northern New Jersey, and Garden City and Merrick, Long Island. Amish Naturals' mission is to increase shareholder value through the sale and distribution of organic, Amish food products to the exploding market for organic and wholesome foods. Last year, the U.S. market for natural/organic foods was estimated to have totaled approximately $13.8 billion. Building on generations of traditions, the company has created food that reflects the wholesomeness and purity of the Amish people and their culinary customs. For more information, please visit www.amishnaturals.com.

For more info: http://FBTX.realpennies.com

(NasdaqGS:FBTX) Franklin Bank Corp. (February 1, 2008), the parent company of Franklin Bank, S.S.B., today announced a net loss of approximately $45.2 million or $1.85 per diluted share for 2007 compared to earnings of $15.5 million or $0.65 per diluted share for 2006. The net loss was primarily due to Franklin's non-cash estimated impairment of goodwill of $65.0 million and an increase to the loan loss allowance of $23.5 million in the fourth quarter. Franklin Bank Corp. operates as the bank holding company for Franklin Bank, S.S.B., a savings bank that provides community banking products and services, and commercial banking services to corporations and other business clients, and originates single family residential mortgage loans primarily in Texas.

The bank, through its community banking offices, offers various consumer banking products, including checking, money market, and savings accounts, certificates of deposit, auto loans, home improvement loans, home equity loans, and mortgage loans, as well as investment services. It also provides commercial banking services, such as financing for single family builders and commercial real estate, including retail, industrial, office buildings, and multi-family properties; and mortgage banking warehouse lines. In addition, the bank involves in mortgage banking activities and originates mortgage loans through retail and wholesale channels.

As of December 31, 2006, it operated 38 community banking offices in Texas; 7 regional commercial lending offices in Florida, Arizona, Michigan, Pennsylvania, Colorado, California, and Washington D.C.; and 37 retail mortgage origination offices in 19 states in the United States. The company, formerly known as BK2, Inc., was founded in 1993 and is based in Houston, Texas.

For more info: http://actc.realpennies.com

Advanced Cell Technology, Inc. (OTCBB:ACTC)(February 1, 2008) today announced that it completed discussions with the Food and Drug Administration (FDA) regarding its retinal pigmented epithelial (RPE) cell therapy through a type B, pre-Investigational New Drug (pre-IND) meeting concerning the regulatory pathway and requirements to file an IND to initiate human clinical trials.

ACT is working with the agency to fulfill the FDA's requirements to bring its RPE cell therapy into human clinical trials for the treatment of retinal degenerative diseases such as Retinitis Pigmentosa, Stargardt's disease, and dry age-related macular degeneration (AMD). The RPE cells are derived from human embryonic stem cells created from ACT single blastomere cell lines under GMP compliant conditions. ACT is moving forward with its characterized RPE manufacturing process to complete the final stages of the company's preclinical testing. Should ACT successfully file an IND for its RPE therapy, the company plans to move forward with Phase I human clinical trials. ACT's Myoblast therapy, an autologous adult stem cell therapy for the treatment of heart failure, has already successfully completed Phase I human clinical trials and is moving into Phase II human clinical trials shortly.

Advanced Cell Technology, Inc. is a biotechnology company applying embryonic stem cell technology in the emerging field of regenerative medicine. The company operates facilities in Alameda, California and Worcester, Massachusetts.

Read our full disclaimer at: http://www.realpennies.com/start.html

Investors are advised that this analysis is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy. This report does not have regard to the specific investment objectives, financial situation and the particular needs of any specific person who may receive this information. The information contained herein is based on sources that we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. Past performance is no guarantee of future results. Please consult a broker before purchasing or selling any securities mentioned on RealPennies. For more movers: http://www.realpennies.com/wrapup.html

Any opinions expressed herein are statements of our judgment as of the date of publication and are subject to change without notice.
Sitemap: http://www.realpennies.com/sitemap.html

RealPennies .

Telephone: 1-800-940-6559

Matt /at/ realpennies.com